CONGRESS ABSTRACT

One treatable cause of pulmonary hypertension (PH) is chronic thromboembolic pulmonary hypertension (CTEPH). In 2022, the ESC Guidelines outlined the treatment algorithm for CTEPH, including multimodal therapy with pulmonary endarterectomy (PEA), PH drugs, and balloon pulmonary angioplasty (BPA). Pretreatment with Riociguat before BPA reduced the frequency of significant BPA-related adverse events by optimizing…

Background: Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure (mPAP) >20 mmHg at rest, as assessed by right heart catheterization (RHC). Echocardiography often serves as the first-line diagnostic examination for patients with suspected PH. However, no echocardiographic estimate of mPAP is currently recommended by guidelines,…

Background. The use and effectiveness of parenteral prostanoids in older patients with pulmonary arterial hypertension (PAH) are unknown. We investigated the association of paretenteral prostanoids use with mortality in elderly PAH patients. Methods. PAH patients aged ≥65 years enrolled in the FOCUS-PAH registry between 2001 and 2023 were included….

Background. Pulmonary arterial hypertension (PAH) is characterized by high morbidity and mortality despite current vasodilator therapies. Sotatercept, a fusion protein targeting the activin signaling pathway, improved exercise capacity and reduced clinical worsening in PAH patients in the STELLAR randomized controlled trial (RCT). This study explored the eligibility for sotatercept…

A 53-year-old female with Crohn’s disease (CD) presented with suspected pulmonary hypertension (PH) and an infiltrative phenotype cardiomyopathy.  The patient was initially treated with infliximab, but due to intolerance, this was suspended and ustekinumab was introduced. Subsequently, mesalazine was administered. Abdominal ultrasound revealed liver cirrhosis, while cardiological assessment showed…